老年人的免疫疗法。也许是肺癌的最佳选择？
Immunotherapy for the elderly. Maybe the best option for lung cancer?
发表日期：2023 Sep 12
作者：
Paul Zarogoulidis, Dimitris Matthaios, Panagoula Oikonomou, Christina Nikolaou, Charalampos Charalampidis, Chrysanthi Sardeli
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS
摘要：
肺癌通常在晚期被诊断，并进行全身性治疗。当前的新诊断技术，如凸面支气管超声、放射性支气管超声、锥形束CT、电磁导航和机器人支气管镜等，为我们提供了高度的诊断结果。这些技术具有微创性，对于合并症（如慢性阻塞性肺疾病和心力衰竭）的患者的诊断几乎没有不良影响。所有这些技术都提供了足够的样本供分子研究使用。自从免疫治疗首次应用以来，我们对于适当的患者目标组有了越来越多的信息。几项已发表的研究将患者分为老年人（≥75岁）和非老年人（≤74岁），并调查了不同药物的不良反应和生存率。在我们目前的评论中，我们提供了有关老年和非老年两组接受免疫治疗和化学免疫治疗的患者的信息。老年患者可以接受这两种组合疗法，并无两组之间的差异，然而，仍需要更多的研究来澄清某些方面。Copyright © 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Lung cancer is usually diagnosed at advanced stage and systematic therapy is administered. New current diagnostic techniques such as the convex-endobronchial ultrasound, radial endobronchial ultrasound, cone beam ct, electromagnetic navigation and robotic bronchoscopy provide us with a high diagnostic yield. These techniques are minimal invasive and patients with comorbidities such as chronic obstructive pulmonary disease and heart failure can be diagnosed with minimal adverse effects. All these techniques provide sufficient sample for molecular investigation. Since immunotherapy was first administered, we have more and more information regarding the appropriate patient target group. Several published studies divided patients as elderly ≥75 and non-elderly ≤74 and investigated the adverse effects of different drugs and survival. In our current commentary we present information on patients receiving immunotherapy versus chemoimmunotherapy in two groups of elderly and non-elderly. Elderly patients can receive both combinations without differences between the two groups, however; more studies are needed to clarify certain aspects.Copyright © 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved.